Inhalable Biopolymer-based Nanocomposites of Nintedanib Esylate: Design, Pharmacokinetics, Cytotoxicity and Antifibrotic Assessment
Authors:
- 2 July 2026
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 9
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Exploring the Albumin Nanoparticles as the Next-Generation Advanced Multifunctional Biomaterials for Inhalation Lung Therapy: Facts, Prospects, and ChallengesBiomedical Materials & Devices, 2025
- Exploring the Potential of Three-Layered Self-assembled Biomaterial-Based Dry Powder Inhaler for Enhanced Structural Integrity and Lung Deposition of Bioactive LysozymeBioNanoScience, 2024
- In silico and experimental studies of bovine serum albumin-encapsulated carbenoxolone nanoparticles with reduced cytotoxicityColloids and Surfaces B: Biointerfaces, 2021
- Bovine Serum Albumin Nanoparticles for the Efficient Delivery of Berberine: Preparation, Characterization and In vitro biological studiesColloids and Surfaces A: Physicochemical and Engineering Aspects, 2021
- Resveratrol-Loaded Microsponge as a Novel Biodegradable Carrier for Dry Powder Inhaler: A New Strategy in Lung DeliveryBioNanoScience, 2020
- Nanofibrous spongy microspheres to deliver rabbit mesenchymal stem cells and anti-miR-199a to regenerate nucleus pulposus and prevent calcificationBiomaterials, 2020
- Clinical Pharmacokinetics and Pharmacodynamics of NintedanibClinical Pharmacokinetics, 2019
- Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeabilityCarbohydrate Polymers, 2019
- Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An UpdateDrugs in R&D, 2017
- Investigating the influence of effective parameters on molecular characteristics of bovine serum albumin nanoparticlesApplied Surface Science, 2015